Cognitive Impairment and Long-Term Cognitive Trajectories in Relation to Incident Sarcopenia Authors: Chao Li, Na Zeng, Fu-Shan Xue Published: 2026 ABSTRACT AbstractBackgroundAlthough sarcopenia is a well-known risk factor for cognitive impairment, the evidence regarding whether cognitive dysfunction may be associated with sarcopenia remains limited. This prospective cohort study aimed to evaluate the association between mild cognitive impairment (MCI), long-term cognitive trajectories, and the development of sarcopenia. We also examined whether a healthy lifestyle could modify this risk.MethodsUsing data from the China Health and Retirement Longitudinal Study, we conducted a 4-year longitudinal study with 7,548 participants. We used Cox proportional hazards regression to assess the link between baseline cognitive function and incident sarcopenia. Generalized estimating equation models explored the role of specific cognitive domains. Latent mixture modeling was used to identify long-term cognitive trajectories and evaluate the modifying effects of lifestyles.ResultsAmong the 7,548 included participants, the mean age was 63.5±6.6 years, and 44.7% were females. Over a 4-year follow-up, we identified 502 new cases of sarcopenia. Baseline MCI was significantly associated with a 57% increased risk of developing sarcopenia (hazard ratio=1.57; 95% confidence interval, 1.25–1.96; p<0.001). Specific cognitive domains, including orientation, memory, and computation, were also significantly linked to sarcopenia. We identified three distinct cognitive trajectories: low (16.6%), moderate (45.6%), and normal (37.8%) function. Compared to the normal group, participants in the low and moderate cognitive function groups had a 2.02-fold and 1.51-fold higher risk of sarcopenia, respectively. A favorable lifestyle was found to significantly reduce the risk of sarcopenia.ConclusionBoth MCI and a persistent low-level decline in cognitive function are strongly associated with an increased risk of sarcopenia, but implementing timely healthy lifestyle interventions can significantly mitigate this risk and promote healthy aging.Keywords: Cognitive dysfunction, Sarcopenia, Prospective studies, Chinese people INTRODUCTION Mild cognitive impairment (MCI) is a common health concern among older adults, with a prevalence rate ranging from 10% to 19%.1,2) This condition is characterized by cognitive decline that exceeds the expected level for an individual's age and education level, but does not substantially impede daily life activities.1-3) According to available data, approximately 10%–15% of individuals with MCI develop dementia each year, and 50%–70% of them develop dementia and Alzheimer's disease within 5 years,1,4) creating substantial challenges for healthcare systems and significantly impacting the well-being of individuals and their families.1,5) Similarly, sarcopenia, a disorder marked by the gradual deterioration of muscle mass, strength, and physical function, poses a significant threat to the health of the elderly population.6) Available literature reveals that the prevalence of sarcopenia increases with age, which affects roughly 10% of individuals over 65 years and rising to 20%–33.1% among men beyond 80 years, with variation according to diagnostic methods.7-9) Sarcopenia can not only increase the risks of falls,10) fractures,10) functional disability,11) and even death,12) but also may limit daily activities,13) raise healthcare costs,14) and place a considerable burden on public health.15) These challenges make it the urgent need for effective prevention strategies. Emerging evidence suggests a significant association between sarcopenia and cognitive impairment, particularly in old population. Sarcopenia may contribute to cognitive decline through the mechanisms such as myokine secretion dysregulation and vascular dysfunction.16) A longitudinal study conducted in an aging Mexican cohort identified baseline sarcopenia as a predictor of increased risk for future MCI.17) Furthermore, specific components of sarcopenia, including low handgrip strength and slow gait speed, have been linked to an increased risk of MCI, further supporting this association.18) Additionally, meta-analyses have demonstrated that sarcopenia is associated with a heightened risk of cognitive impairment, reinforcing the importance of maintaining muscle function for cognitive health.19,20) Although some longitudinal cohort studies have demonstrated sarcopenia preceding cognitive decline,17,21,22) few studies have assessed the opposite direction, that is, whether existing cognitive dysfunction may be associated with the development of sarcopenia.19) Besides, a key clinical characteristic of MCI is progressive cognitive decline over years, making it crucial to consider long-term cognitive trajectories when evaluating its effect on the development of sarcopenia. However, there is a notable lack of systematic evidence on how lifestyle factors may moderate this relationship, leaving significant gaps in our understanding of the bidirectional nature of these conditions. It has been shown that lifestyle factors such as smoking, alcohol consumption, sleep, and body mass index (BMI) may contribute to the development of both sarcopenia and cognitive impairment by promoting inflammation and oxidative stress.15,23,24) Conversely, a lack of social activities may indirectly influence these conditions by reducing physical activity and exacerbating psychological distress.25) This prospective study with a longitudinal design employed the data from the China Health and Retirement Longitudinal Study (CHARLS) to determine the association between cognitive function, long-term cognitive trajectories, and the incidence of sarcopenia. Furthermore, the potential moderating effects of lifestyle factors on this relationship were also assessed. We aimed to provide the evidence that informs the targeted recommendations and interventions for sarcopenia management and prevention, contributing to public health efforts to promote healthy aging. MATERIALS AND METHODS Datasets This study used the CHARLS dataset, spanning the 2011, 2013, and 2015 waves. CHARLS implemented a multistage, stratified, probability-proportionate-to-size sampling design to recruit the individuals from 450 villages or urban communities across 28 provinces of China, as described in previous research.22,26) The present analysis involved participants aged 45 years and above. Ethical Statement This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval for all the CHARLS waves was granted from the Institutional Review Board (IRB) at Peking University (IRB00001052-11015). Furthermore, written informed consents were obtained from all participants who were involved in this study. In addition, this study has been approved by the Institutional Review Board of Beijing Friendship Hospital, Capital Medical University for exemption from the ethical statement for conducting database research (2025-P2-503). Participants First, we enrolled 17,857 participants at the baseline in 2011. Then, we excluded 751 participants who were under 45 years of age, as well as 2,119 participants who did not participate in the cognitive assessment and 1,776 participants who did not report sarcopenia at baseline. Additionally, a total of 14,529 participants were included in the study, all of whom underwent a comprehensive cognitive function and sarcopenia assessment. In addition, we excluded 607 adults who were diagnosed with sarcopenia at baseline, 155 who were lost to follow-up or had passed away, 5,912 who failed to complete sarcopenia assessment during follow-up, and 3,199 who had missing lifestyle assessment at wave 2 and had missing data on other confounders at baseline. This led to a final sample of 7,548 indi-viduals for the final analysis of the associations between cognitive status and sarcopenia risk (Fig. 1). The flow chart of study population. Assessment of Cognitive Function at Baseline As described in previous studies, the CHARLS conducted face-to-face assessments to evaluate participants' cognitive function using the Mini-Mental State Examination (MMSE), which covers four domains: memory, computation, orientation, and drawing.22) Memory dimensions involve immediate and delayed recalls. Each participant's memory ability was evaluated by counting the number of words recalled immediately (immediate word recall) and after the participant completed the survey of depression scale, computation, and drawing tests (delayed word recall) following the random presentation of 10 unrelated Chinese words. The total memory score was 20 points, with one point assigned for each word that was recalled during either immediate or delayed recall task. The computation task required the participants to subtract 7 from 100 five times in succession, with one point awarded for each correct response. The total score of the computation was five points. Orientation task was evaluated by items identifying year, month, day, and the day of the week. The maximum total score of the orientation dimension is 4 points, with one point given for each item. The interviewer assessed the drawing task by presenting a picture of two intersecting pentagons to determine whether the participant could accurately observe and reproduce the image. One point was awarded if correct. The total cognitive score was calculated by summing the scores from memory (20 points), computation (5 points), orientation (4 points), and drawing (1 point), with a maximum score of 30 points and a higher score indicating a better cognitive function. In our study, MCI was defined as being at least 1 standard deviation (SD) below the age standard according to aging-associated cognitive decline (AACD).27) Participants were stratified into groups according to 5-year age intervals. Within each age group, individuals who met the AACD criteria were classified as having MCI.22) Sarcopenia Assessment Sarcopenia was operationalized based on the Asian Working Group for Sarcopenia (AWGS) 2019 diagnostic framework, including evaluations of physical performance, an equation-estimated appendicular skeletal muscle mass (ASM), and muscle strength.28) Handgrip strength was measured in kilograms (kg) using a Yuejian WL-1000 dynamometer (Nantong Yuejian Physical Measurement Instrument Co., Ltd., Nantong, China) for both dominant and non-dominant hands. Two measurements were recorded for each hand, with the dynamometer held at a right angle (90°), and participants were instructed to exert maximal force while squeezing. The mean value of the maximum strength data was used for analysis. If measurement of one hand was impossible for any reason, the highest score from the other hand was recorded. According to the AWGS 2019 criteria, a low handgrip strength is defined as less than 28 kg for men and less than 18 kg for women. Because dual-energy X-ray absorptiometry (DXA)/bioelectrical impedance analysis (BIA) measurements were not available in the CHARLS dataset, ASM was estimated using a previously developed anthropometric equation for Chinese adults: ASM = 0.193 × weight (kg) + 0.107 × height (cm) − 4.157 × sex − 0.037 × age (years) − 2.631, where sex was coded as 1 for men and 2 for women. This equation has been cross-validated against DXA-measured ASM in Chinese adults and has demonstrated a satisfactory predictive performance.22,29) The subjects' weight and height were measured using an Omron HN-286 scale (Omron Co., Kyoto, Japan) and a Seca 213 height meter (Seca GmbH, Hamburg, Germany), respectively. Because the CHARLS does not include the DXA/BIA measurements, ASM was estimated using a validated anthropometric equation, and a sarcopenia diagnosis was constructed by operationalizing the AWGS 2019 diagnostic framework with estimated ASM, consistent with previous CHARLS-based studies.22,30) Previous validation work had reported a strong correlation between the equation-estimated ASM and the DXA-derived ASM in the Chinese populations.31) Nevertheless, because ASM was not directly measured in the CHARLS, some degree of misclassification is possible. To define low muscle mass, the sex-specific lowest 20th percentile of height-adjusted muscle mass (ASM/height²) within the study cohort was used as the threshold. These values are <5.29 kg/m² for women and <6.99 kg/m² for men, according to the findings of previous work.32) During the physical performance evaluation, the five times sit-to-stand test (FTSST), the Short Physical Performance Battery (SPPB), and gait speed were assessed. To evaluate gait speed, participants were instructed to walk a distance of 2.5 meters at their usual pace, with completion times recorded over two trials. The FTSST measured the time required for participants to rise consecutively from a seated position on a chair with a 47-cm-high seat.22) The Short Physical Performance Battery (SPPB) consists of three components: a standing balance test, a 2.5-m gait-speed test, and a five-times sit-to-stand test. For the balance test, participants performed side-by-side, semi-tandem, and tandem stances, each held for up to 10 seconds. The balance component was scored from 0 to 4 points according to performance across the three stances. Gait speed was assessed over 2.5 m, with completion times recorded over two trials. Lower-extremity strength was assessed by the time required to rise from a chair five times without using the arms (0–4 points). A cumulative score of 12 was assigned, with up to 4 points awarded for each test. According to the AWGS 2019 guidelines, inadequate physical performance was defined as a gait speed below 1.0 m/s, a FTSST time of 12 seconds or more, or an SPPB score of less than 9. In sum, sarcopenia is characterized by an accompanying reduction in muscle mass, strength, or physical performance. Consequently, participants were categorized into two groups: non-sarcopenia and sarcopenia. Definition of Healthy Lifestyles According to previous studies,26,33,34) this study assessed five lifestyle factors: physical activity, alcohol consumption, smoking, BMI, and sleep duration. Each factor was assigned a score of 1 for healthy behavior and 0 for unhealthy behavior. Engaging in vigorous (e.g., heavy lifting, cycling with a large load, aerobics) or moderate (e.g., regular cycling, tai chi, brisk jogging) activities for a minimum of 30 minutes on three separate occasions per week was established as physical activity. Scores of 1 were allocated to participants who met this criterion, while scores of 0 were assigned to those who did not. Smoking status was categorized into three categories: current smoker, former smoker, and never smoker. Individuals who had never smoked were allocated a score of 1, while those who had smoked were assigned a score of 0. Participants who had never consumed alcohol received a score of 1, while those who had consumed alcohol received a score of 0. Alcohol consumption was classified as current, former, or never consuming. A BMI of 18.5–24.9 kg/m² was regarded as healthful. Participants were assigned a sleep score of 1 if they reported sleeping for a minimum of 6 hours each night, and 0 otherwise. An overall lifestyle score was determined, with a range of 0 to 5, where a higher score meant a strict adherence to healthful lifestyle practices. Five individual factors were combined to calculate this total score. Participants were divided into three categories based on their overall score: favorable lifestyle (4–5), intermediate lifestyle (2–3), and unfavorable lifestyle (0–1).35,36) To elucidate the assumed causative framework, we developed a directed acyclic graph demonstrating the associations among baseline cognitive impairment, lifestyle factors, measured covariates and occurrence of sarcopenia (Supplementary Fig. S1). Assessment of Potential Covariates The covariates were assessed in accordance with the findings of earlier studies.20,22) Education levels (illiterate, elementary school, middle school, high school, university degree or higher), marital status (married, separated, and unmarried/divorced/widowed), household incomes (<1,000, 1,000–4,999, 5,000–9,999, 10,000–19,999, and ≥20,000 Chinese yuan), smoking status (never, current, former), alcohol consumption (never, current, former), sleep duration, and BMI were all potential confounders. The sleep duration was self-reported by participants with the question “In the past month, how many hours on average did you actually sleep each night? (This may be shorter than the time you spent lying in bed.)” BMI was calculated from height and weight. Height was measured using a Seca 213 stadiometer, and weight was measured using an Omron HN-286 scale. In addition, frailty was considered as a potential confounder of the association between MCI and sarcopenia. We therefore adjusted for baseline frailty using a 29-item frailty index (FI) previously developed and validated in the CHARLS. The FI was constructed by summing the deficits across 29 items and dividing by the total number of items,37) with a higher score indicating greater frailty, and it was included as a continuous covariate in the multivariable models. Statistical Analysis Data analyses were conducted using SAS software version 9.4 (SAS Institute, Cary, NC, USA) and R programming language version 4.4.3 (The R Foundation, Vienna, Austria). Graphs were produced using the ggplot2 package. Continuous variables were reported as means with standard deviations (SD) for normally distributed data or as medians with interquartile ranges (IQR) for non-normally distributed data. Categorical variables were presented as counts and percentages. The t-test or Wilcoxon rank sum test was utilized to evaluate the differences between the MCI group and the non-MCI group. The chi-square test was conducted to assess the differences among groups of categorical variables. The Kaplan-Meier method was used to determine the 4-year cumulative incidence of sarcopenia, while a Cox proportional hazards model and hazard ratios (HR) were employed to evaluate the relationship between MCI and sarcopenia. Two models were developed to assess the relationship between the status of MCI and the risk of developing sarcopenia. Model 1 is adjusted for age and sex; Model 2 is further adjusted for residential regions, education levels, marital status, mean household incomes, smoking status, alcohol consumption, sleep duration, and BMI. In sensitivity analyses, the participants who developed sarcopenia within the first 2 years of follow-up and those with possible preclinical sarcopenia at baseline, defined as low handgrip strength or slow gait speed, were excluded to reduce the potential for reverse causality. In addition, to account for selection bias due to participants' exclusion, we performed an inverse probability weight analysis to further assess our findings. A competing risk model was developed, considering loss to follow-up and death as competing events to mitigate potential biases in outcome assessment. To further estimate the relationship between baseline MMSE scores and future sarcopenia occurrence in 2013 and 2015, we employed a generalized estimating equation (GEE) model with a binomial distribution and a logit link. Repeated measures of sarcopenia within participants were accounted for by specifying an exchangeable correlation structure. The model adjusted for potential confounders, including age, sex, comorbidities, and baseline sarcopenia status. We estimated the odds ratio (OR) with 95% confidence interval (CI) of the association between baseline MMSE scores and sarcopenia. We assessed the interaction between MMSE scores and time in the GEE model, but the interaction was not statistically significant and subsequently excluded from the model. We performed the latent mixture modeling to identify subgroups with similar underlying trajectories of cognitive function. To achieve this, we evaluated the models with varying numbers of classes and functional forms (including intercept-only, linear, and quadratic slopes). Model fit was assessed using the Bayesian Information Criterion (BIC). Initially, we specified a model with five classes, all in quadratic form, and subsequently compared its BIC values with those of models containing four, three, two, and one class. The model with three classes demonstrated the best fit. We then further refined our analysis by comparing the BIC values of models with different functional specifications. Ultimately, the optimal model consisted of two classes with linear terms and one class with a quadratic term. We calculated the mean posterior probability of final group membership to evaluate the model's discriminative ability. Subgroup analysis was conducted to explore the associations between long-term cognitive function patterns (low, moderate, and normal cognitive function) and the risk of developing sarcopenia. Additionally, we assessed the relationship between a composite healthy lifestyle and the overall risk of sarcopenia within subgroups defined by long-term cognitive function patterns using a logistic regression model. Further, we conducted sensitivity analyses using alternative lifestyle definitions. First, we reconstructed the lifestyle score after excluding BMI to reduce the potential correlation between BMI and equation-estimated ASM. Second, we constructed a regression coefficient–weighted lifestyle score using the non-BMI lifestyle components. The weighted scores were categorized into the tertiles and analyzed using the same covariate adjustments as in the main analysis. Third, we examined the associations between each non-BMI lifestyle component and incident sarcopenia. All statistical tests were two-sided, and a p-value <0.05 was considered statistically significant. RESULTS Baseline Characteristics The mean age of 7,548 included participants was 63.5±6.6 years and 55.4% of them (n=4,178) were males. At baseline assessment, 1,142 (15.1%) participants reported MCI. Among those with MCI, 441 (38.6%) were male and 701 (61.4%) were female. Participants who reported MCI were more likely to live in rural area, have a lower education level and a lower average household income (Table 1). The median follow-up time of this study was 4.0 years (IQR, 3.9–4.0) (Supplementary Table S1). Table 1.The characteristics of participants with and without MCI at baselineVariableTotal (n=7,548)No MCI (n=6,406)MCI (n=1,142)p-valuesAge (y)63.50±6.6363.52±6.6463.41±6.630.624Sex<0.001 Male4,178 (55.35)3,737 (58.34)441 (38.62) Female3,370 (44.65)2,669 (41.66)701 (61.38)Residential areas<0.001 Urban2,942 (38.98)2,645 (41.29)297 (26.01) Rural4,606 (61.02)3,761 (58.71)845 (73.99)Education levels<0.001 Illiterate2,053 (27.20)1,329 (20.75)724 (63.40) Primary school3,659 (48.48)3,276 (51.14)383 (33.54) Middle school1,213 (16.07)1,183 (18.47)30 (2.63) High school/vocational high school493 (6.53)488 (7.62)5 (0.44) Junior college or above130 (1.72)130 (2.03)0 (0.00)Household incomes (CNY)<0.001 <1,0003,027 (40.10)2,547 (39.76)480 (42.03) 1,000–4,9991,135 (15.04)904 (14.11)231 (20.23) 5,000–9,999574 (7.60)463 (7.23)111 (9.72) 10,000–19,999770 (10.20)653 (10.19)117 (10.25) ≥20,0002,042 (27.05)1,839 (28.71)203 (17.78)Marital status<0.001 Married5,981 (79.24)5,132 (80.11)849 (74.34) Separated233 (3.09)194 (3.03)39 (3.42) Unmarried/divorced/widowed1,334 (17.67)1,080 (16.86)254 (22.24)Ever/current smoke<0.001 No3,664 (48.56)2,986 (46.63)678 (59.37) Yes2,207 (29.25)1,927 (30.10)280 (24.52) Ever smoke1,674 (22.19)1,490 (23.27)184 (16.11)Ever/current alcohol<0.001 No3,842 (50.90)3,184 (49.70)658 (57.62) Yes2,534 (33.57)2,245 (35.05)289 (25.31) Ever alcohol1,172 (15.53)977 (15.25)195 (17.08)Daily sleep times (hr)6.50 (5.38–7.33)6.50 (5.50–7.33)6.33 (5.12–7.33)0.073Healthy lifestyles0.314 Non-healthy lifestyle1,150 (15.24)975 (15.22)175 (15.32) Intermediate healthy lifestyle2,966 (39.30)2,496 (38.96)470 (41.16) Healthy lifestyle3,432 (45.47)2,935 (45.82)497 (43.52)Comorbidities Cancer56 (0.74)50 (0.78)6 (0.53)0.462 Chronic lung disease917 (12.16)777 (12.14)140 (12.27)0.941 Cardiovascular diseases1,190 (15.78)1,059 (16.54)131 (11.50)<0.001 Stroke200 (2.65)165 (2.58)35 (3.07)0.393 Arthritis2,728 (36.17)2,253 (35.19)475 (41.67)<0.001 Dyslipidemia826 (10.96)743 (11.61)83 (7.29)<0.001 Hepatic diseases248 (3.29)212 (3.31)36 (3.16)0.858 Kidney diseases419 (5.56)357 (5.58)62 (5.45)0.915 Digestive system diseases1,674 (22.20)1,411 (22.04)263 (23.07)0.464 Asthma822 (13.15)687 (10.72)135 (14.15)0.346 Memory-related diseases73 (0.97)62 (0.97)11 (0.97)0.995 Hypertension2,453 (32.52)2,102 (32.84)351 (30.76)0.179 Diabetes689 (9.23)602 (9.51)87 (7.68)0.057BMI (kg/m2)23.32 (21.09– 25.88)23.39 (21.15– 25.94)22.86 (20.82– 25.40)0.206Values are presented as mean±standard deviation, median (interquartile range), or number (%).MCI, mild cognitive impairment; BMI, body mass index; CNY, Chinese yuan. The characteristics of participants with and without MCI at baseline Values are presented as mean±standard deviation, median (interquartile range), or number (%). MCI, mild cognitive impairment; BMI, body mass index; CNY, Chinese yuan. MCI at Baseline and Risk of Sarcopenia During the follow-up with a total of 30,030.9 person-years, 502 cases of incident sarcopenia were identified. The 4-year cumulative incidence of sarcopenia was 10.5% (95% CI, 8.5–12.4) in the MCI group compared to 6.4% (95% CI, 5.7–7.1) in the no-MCI group (p<0.001). The baseline MCI (HR=1.57; 95% CI, 1.25–1.96) was significantly associated with an increased risk of developing sarcopenia after multivariable adjustments (p<0.001, Table 2). Among middle-aged participants (n=2,465), 54 cases of incident sarcopenia occurred during 9,813.0 person-years of follow-up. The 4-year cumulative incidence of sarcopenia was 10.1% (95% CI, 4.0–16.3) in the MCI group compared to 3.6% (95% CI, 2.2–5.0) in the non-MCI group. Middle-aged participants with baseline MCI had a 2.47 (95% CI, 1.26–4.84) fold higher risk of incident sarcopenia compared to those without baseline MCI (p=0.0085, Table 2). In older participants, 448 cases of incident sarcopenia were observed during 20,217.9 person-years of follow-up. The 4-year cumulative incidence of sarcopenia was 13.8% (95% CI, 11.2–16.6) in the MCI group versus 8.6% (95% CI, 7.6–9.6) in the non-MCI group. For older participants, baseline MCI significantly elevated the risk of sarcopenia (HR=1.47; 95% CI, 1.16–1.87; p=0.0015) (Table 2). Furthermore, the results remained consistent in sensitivity analyses excluding early incident sarcopenia cases, participants with baseline or early-onset frailty, and those with possible preclinical sarcopenia at baseline. In addition, the inverse-probability weighting analysis also supported the robustness of our findings (Supplementary Table S2). Table 2.The associations between baseline MCI and risk of sarcopeniaNo MCIMCIp-valueOverall population (n=7,548) Number of participants6,4061,142 Number of sarcopenia382120 Follow-up, person-years25,492.344,538.59 Follow-up, years4.00 (3.91–4.00)4.00 (3.91–4.00) HR (95% CI) for sarcopenia UnadjustedReference1.75 (1.42–2.15)<0.001 Adjusted model 1Reference1.94 (1.58–2.39)<0.001 Adjusted model 2Reference1.57 (1.25–1.96)<0.001Middle-aged participants with age <60 years (n=2,465) Number of participants2,087378 Number of sarcopenia3915 Follow-up, person-years8,307.291,505.75 Follow-up, years4.00 (3.91–4.00)4.00 (3.91–4.00) HR (95% CI) for sarcopenia UnadjustedReference2.14 (1.18–3.89)0.0122 Adjusted model 1Reference2.24 (1.23–4.09)0.0088 Adjusted model 2Reference2.47 (1.26–4.84)0.0085Older participants with age ≥60 years (n=5,083) Number of participants4,319764 Number of sarcopenia343105 Follow-up, person-years17,185.053,032.84 Follow-up, years4.00 (3.91–4.00)4.00 (3.91–4.00) HR (95% CI) for sarcopenia UnadjustedReference1.72 (1.38–2.14)<0.001 Adjusted model 1Reference1.90 (1.53–2.37)<0.001 Adjusted model 2Reference1.47 (1.16–1.87)0.0015Values are presented as median (interquartile range) except for specially stated.MCI, mild cognitive impairment; HR, hazard ratio; CI, confidence interval.Model 1 was adjusted for age and sex; model 2, additionally adjusted for residential regions, education levels, average household incomes, marital status, status of smoking and alcohol intake. The associations between baseline MCI and risk of sarcopenia Values are presented as median (interquartile range) except for specially stated. MCI, mild cognitive impairment; HR, hazard ratio; CI, confidence interval. Model 1 was adjusted for age and sex; model 2, additionally adjusted for residential regions, education levels, average household incomes, marital status, status of smoking and alcohol intake. Cognitive Score and Risk of Developing Sarcopenia Table 3 summarizes the results of the association between total score of MMSE, including its various dimensions related to cognitive function, and incident sarcopenia using GEE model. As shown in Table 3, lower scores in the total MMSE score, orientation, memory, and computation were all significantly associated with an increased risk of incident sarcopenia. Specifically, the odds ratios for developing sarcopenia were 0.93 (95% CI, 0.90–0.95), 0.83 (95% CI, 0.76–0.91), 0.91 (95% CI, 0.88–0.94), and 0.88 (95% CI, 0.82–0.94) per 1-SD increase in the scores for MMSE, orientation, memory, and computation, respectively (Table 3). Table 3.Baseline cognitive score and risk of sarcopeniaCognitive scoreAge- and sex-adjusted modelMultivariable-adjusted modelOR (95% CI) per SD increasep-valueOR (95% CI) per SD increasep-valueTotal score0.89 (0.87–0.91)<0.0010.93 (0.90–0.95)<0.001Orientation0.76 (0.71–0.83)<0.0010.83 (0.76–0.91)<0.001Memory0.89 (0.86–0.92)<0.0010.91 (0.88–0.94)<0.001Computation0.84 (0.79–0.89)<0.0010.88 (0.82–0.94)0.001Drawing0.66 (0.54–0.81)<0.0010.87 (0.68–1.10)0.2509OR, odds ratio; CI, confidence interval. Baseline cognitive score and risk of sarcopenia OR, odds ratio; CI, confidence interval. Long Term Pattern of MCI and Risk of Sarcopenia Three discrete trajectories in cognitive scores during the 4-year span were identified (Fig. 2): 1,254 participants (16.6%) maintained a low level of cognitive function throughout 4 years (low cognitive function group; MMSE score median range, 6.0 to 7.0); 3,439 (45.6%) had a stable medium cognitive function (medium cognitive function group; MMSE score median range, 12.0 to 13.0); and 2,855 (37.8%) maintained a high level of cognitive function during 4 years (normal cognitive function group, MMSE score median range, 17.0 to 18.0). Mean±SD probabilities of each each individual belonged to their final group were 0.91±0.13, 0.89±0.13 and 0.91±0.13 across the trajectory groups. The basic characteristics of participants at baseline by cognitive trajectories are shown in Supplementary Table S3. The trajectories of long term cognitive function of the participants. MMSE, Mini-Mental State Examination. The results of subgroup analysis by cognitive function trajectories are shown in Table 4. Compared with participants having a normal cognitive function, those with a low cognitive function demonstrated a 2.02-fold (1.45–2.82) higher risk of incident sarcopenia, and participants with a medium cognitive function showed a 1.51-fold (1.16–1.99) higher risk of sarcopenia. Moreover, the same effect was detected in the older participants and those with low cognitive function middle-aged adults. Table 4.Associations between MMSE trajectories during 2011 to 2015 with the risk of developing sarcopeniaCognitive functionNormalMediumLowOverall population (n=7,548) Number of participants2,8553,4391,254 Number of sarcopenia107235167 OR (95% CI) for sarcopenia UnadjustedReference1.89 (1.49–2.38)3.95 (3.06–5.08) Age- and sex-adjusted modelReference1.65 (1.30–2.10)2.76 (2.11–3.62) Multivariable-adjusted modelReference1.51 (1.16–1.99)2.02 (1.45–2.82)Middle-aged participants with age <60 years (n=2,465) Number of participants1,0721,104289 Number of sarcopenia172512 OR (95% CI) for sarcopenia UnadjustedReference1.44 (0.78–2.68)2.69 (1.27–5.70) Age- and sex-adjusted modelReference1.47 (0.79–2.74)2.90 (1.35–6.26) Multivariable-adjusted modelReference1.52 (0.77–3.01)3.53 (1.42–8.78)Older participants with age ≥60 years (n=5,083) Number of participants1,7832,335965 Number of sarcopenia78218152 OR (95% CI) for sarcopenia UnadjustedReference2.25 (1.72–2.94)4.09 (3.07–5.43) Age- and sex-adjusted modelReference2.00 (1.53–2.63)3.13 (2.31–4.24) Multivariable-adjusted modelReference1.49 (1.11–2.01)1.88 (1.32–2.70)MMSE, Mini-Mental State Examination; OR, odds ratio; CI, confidence interval. Associations between MMSE trajectories during 2011 to 2015 with the risk of developing sarcopenia MMSE, Mini-Mental State Examination; OR, odds ratio; CI, confidence interval. Joint Analysis of Lifestyle and Cognitive Impairment with Incident Sarcopenia The combined effects of cognitive impairment and lifestyle categories on sarcopenia incidence are presented in Fig. 3 and Table 5. Using the unfavorable lifestyle group as the reference category, participants with intermediate and favorable lifestyles demonstrated a dose-response reduction in the risk of developing sarcopenia in both the overall population and cognitive-stratified subgroups. In the overall population, those with an intermediate lifestyle had a 55% reduction in the risk of sarcopenia (HR=0.45; 95% CI, 0.34–0.60), while a favorable lifestyle was associated with a 64% reduction in the risk of sarcopenia (HR=0.36; 95% CI, 0.25–0.53). This pattern remained consistent across cognitive-stratified subgroups, with the strongest protective effect observed in the individuals with normal cognitive function. Notably, even among participants with a persistently low cognitive function, intermediate and favorable lifestyles reduced the risk of sarcopenia by 58% (HR=0.42; 95% CI, 0.24–0.75) and 72% (HR=0.28; 95% CI, 0.13–0.62), respectively. In sensitivity analyses, the association between a favorable lifestyle pattern and a lower risk of incident sarcopenia remained generally consistent after BMI was excluded from the lifestyle score, when a regression coefficient–weighted lifestyle score was used, and when lifestyle factors assessed at wave 1 were used (Supplementary Table S4). Significant trends across lifestyle categories were also observed in alternative models. The associations of healthy lifestyle with the risk of developing sarcopenia in different long-pattern of cognitive function population. All HRs were calculated by adjusting age, sex, residential region, education level, average household income and marital status. CI, confidence interval; HR, hazard ratio. Table 5.The risk of developing sarcopenia according to levels of cognitive function and lifestylesNumber of sarcopeniaPerson-yearsHR (95%CI)p for trendOverall population<0.001 Unfavorable lifestyle1949,526.63Reference Intermediate lifestyle699,931.340.45 (0.34–0.60) Favorable lifestyle399,791.940.36 (0.25–0.53)Low cognitive function0.0003 Unfavorable lifestyle881,411.27Reference Intermediate lifestyle481,637.060.42 (0.24–0.75) Favorable lifestyle281,628.810.28 (0.13–0.62)Medium cognitive function0.0004 Unfavorable lifestyle894,533.64Reference Intermediate lifestyle374,546.170.50 (0.30–0.85) Favorable lifestyle234,546.170.52 (0.34–0.78)Normal cognitive function0.0004 Unfavorable lifestyle503,581.73Reference Intermediate lifestyle133,748.110.32 (0.17–0.63) Favorable lifestyle63,748.110.18 (0.07–0.49)HR, hazard ratio; CI, confidence interval. The risk of developing sarcopenia according to levels of cognitive function and lifestyles HR, hazard ratio; CI, confidence interval. DISCUSSION This large-scale prospective cohort study, including 7,548 participants with a 4-year follow-up, is the first to examine the associations between chronic MCI, long-term cognitive function patterns, and sarcopenia occurrence, as well as potential strategies to mitigate MCI-induced sarcopenia in the Chinese middle-aged and older population. Our findings revealed that the participants with baseline MCI had a 57% higher risk of developing sarcopenia compared to those without baseline MCI. Additionally, lower cognitive assessment scores, particularly in the orientation domain, were associated with an increased risk of developing sarcopenia. Regarding long-term cognitive function patterns, the individuals with a low cognitive function had a 2-fold higher risk of developing sarcopenia compared to those with normal cognitive function, while those with a medium cognitive function had a 1.5-fold increased risk. Moreover, adopting favorable and intermediate lifestyles significantly reduced the risk of sarcopenia associated with chronic MCI by 69% and 58%, respectively. Overall, our study aligns with previous findings regarding the relationships between cognitive function and sarcopenia.38,39) A previous longitudinal study demonstrated a bidirectional relationship between sarcopenia status and cognitive function in older Chinese adults.38) Furthermore, a Mendelian randomization study found that lower walking speed, muscle strength, and muscle mass were significantly associated with poorer cognitive performance, suggesting a mutually reinforcing relationship.39) Importantly, a review further highlighted that cognitive status was associated with the progressive decline of muscle strength, indicating that MCI may gradually increase the risk of muscle weakness by reducing physical activity or affecting neuromuscular control.40) In the specific analysis, orientation, memory, and computation but not drawing were significantly associated with incident sarcopenia. This may be because these areas are proxies for larger cognitive abilities in attention, planning, self-care, physical exercise and nutritional practices that are tightly linked to muscle health. On the other hand, the drawing task was measured by only one item, which could have lower variability and statistical power.41) Nevertheless, the relationship between cognitive function, particularly its long-term trajectory, and the development of sarcopenia has been largely overlooked in previous works. To the best of our knowledge, only a limited number of studies have examined the temporal relationship between cognitive function and sarcopenia. In the available literature, only one Brazilian cohort investigated the association between baseline MCI and sarcopenia development and reported a 2.44-fold increased risk.42) Evidently, our study extended this research by exploring the impacts of cognitive trajectories and the independent influences of specific cognitive domains, such as orientation, memory, and computation, on the development of sarcopenia. Given the limited works regarding the relationship between cognition impairment and the risk of developing sarcopenia, our study fills this knowledge gap and further clarifies the distinct contributions of different cognitive dimensions to the pathophysiology of sarcopenia. As mentioned above, the shared underlying mechanisms linking cognitive impairment and sarcopenia may include inflammation, myokines, vascular dysfunction, and common risk factors such as physical inactivity. Chronic inflammation, characterized by elevated pro-inflammatory cytokine levels such as IL-6, is a hallmark of both cognitive impairment and sarcopenia, contributing to muscle protein breakdown and neuronal damage.43) Conversely, myokines, such as irisin and cathepsin-B secreted by muscles, play a crucial role in brain health. Disruptions in myokine secretion may contribute to cognitive decline, creating a feedback loop that exacerbates muscle loss.16) Vascular dysfunction, including atherosclerosis, can compromise blood flow to both the muscles and the brain, impairing their function.43) Furthermore, the shared risk factors such as physical inactivity reduce both muscle engagement and cognitive stimulation, while poor nutrition accelerates muscle catabolism and is linked to cerebral white matter hyperintensities. Additionally, hormonal changes, such as decreased testosterone levels, further compound these effects, highlighting the complex interaction between sarcopenia and cognitive decline.44,45) There is limited evidence as to how lifestyles modify the association between cognitive impairment and sarcopenia. Smoking, a common risk factor for both cognitive impairment and sarcopenia, may exacerbate this association by simultaneously compromising brain health and muscle function through heightened inflammatory responses and oxidative stress.44,46) The impact of alcohol consumption on the relationship between cognitive impairment and sarcopenia is complex—moderate drinking may have no significant effect, whereas heavy alcohol consumption may elevate the risk of both conditions, potentially by affecting nutritional status and physical activity levels.47) BMI may modify the relationship between cognitive impairment and sarcopenia by influencing body compositions and overall health. For example, cognitive impairment may be related to dietary behavior changes, which in turn affect BMI and subsequently alter the risk of developing sarcopenia.48) Social engagement may mitigate the impact of cognitive impairment on sarcopenia by helping maintain physical activity levels and reducing the risk of muscle loss.49) Similarly, good sleep quality may protect against both conditions and lessen the adverse effects of cognitive impairment on the development of sarcopenia. For instance, sleep disturbances resulting from cognitive impairment may further increase the risk of developing sarcopenia.50) Limitation The primary novelty of this study lies in examining the relationships between both baseline and long-term patterns of cognitive function, and the development of sarcopenia, as well as how favorable lifestyles modify the impact of MCI on the development of sarcopenia. However, several potential limitations should be noted. First, as this was an observational study, it can only establish an association between chronic MCI and the risk of developing sarcopenia, rather than a causal relationship. Given the shortage of detailed data regarding disease management (such as severity, medication adherence and treatment status) in the CHARLS datasets used in this study, residual confounding associated with disease management cannot be entirely ruled out, and the observed association may be partially attributed to inadequate management of comorbidities. Second, muscle mass was not directly measured in the CHARLS datasets; therefore, ASM was estimated using an anthropometric equation rather than the DXA/BIA. Although this approach has been validated against the DXA in external Chinese samples, it still may lead to misclassification of sarcopenia-related outcomes. Besides, ASM was partly derived from body weight, height and age. Because BMI was also included in the healthy lifestyle score, the association between lifestyle score and sarcopenia may partly reflect the structural correlation between BMI and equation-estimated ASM. Although we have additionally performed sensitivity analyses excluding BMI from the lifestyle score, the lifestyle-related findings should be interpreted with caution. Third, the exclusion of participants who fail to offer data on MCI or sarcopenia may have introduced selection bias. Consequently, the findings may not fully reflect the entire population of Chinese community-dwelling adults, and caution should be exercised when generalizing our results. Fourth, cognitive function was assessed at wave 1, whereas lifestyle factors were assessed at wave 2. Thus, the lifestyle behaviors measured after baseline may have partly reflected behavioral changes related to early cognitive impairment. That is, the lifestyle-related findings should be interpreted as the associations with behavioral patterns during follow-up rather than the evidence of a strictly baseline independent modifying effect. Additionally, lifestyle factors may partially contribute to the progression from mild cognitive impairment to the onset of sarcopenia. The correction for lifestyle-related factors in the multivariable models may have led to potentially underestimating the association between MCI and sarcopenia. Thus, future studies are still needed to clarify the causal relationship and explore the potential mechanisms underlying the association between baseline MCI and the risk of developing sarcopenia. Conclusion This study demonstrates that baseline MCI, particularly a long-term cognitive decline, is significantly associated with an increased risk of developing sarcopenia-related outcomes among middle-aged and older adults in China. However, healthy lifestyle factors may potentially mitigate the risk of sarcopenia induced by baseline MCI. Our findings highlight the potential of advocating healthy lifestyle practices at the community level as an effective strategy to reduce the incidence of sarcopenia and promote healthy aging. Footnotes CONFLICT OF INTEREST The researchers claim no conflicts of interest. FUNDING None. AUTHOR CONTRIBUTIONS Study design: CL, NZ, FSX; Data collection: CL, NZ; Writing of paper: CL, NZ; Manuscript revision: FSX; Statistical analysis: NZ, CL; Data interpretation: CL, NZ, FSX; Final approval of the version to be published: all authors. DATA AVAILABILITY All individual de-identified participant data collected during this study can be available to investigators whose proposed use of the data has been approved by an independent committee. Proposals, with a signed data access agreement, should be directed to the corresponding author. SUPPLEMENTARY MATERIALS Supplementary materials can be found via https://doi.org/10.4235/agmr.26.0026. Baseline characteristics of participants of included participants and those excluded Sensitivity analysis regarding risk of sarcopenia with baseline cognitive status Baseline characteristics of participants across different patterns of long-term cognitive function Sensitivity analyses of the association between alternative lifestyle definitions and incident sarcopenia A directed acyclic graph depicting the causative relationships among baseline cognitive impairment, lifestyle variables, and the occurrence of sarcopenia. MCI, mild cognitive impairment. REFERENCES Associated Data Supplementary Materials Baseline characteristics of participants of included participants and those excluded Sensitivity analysis regarding risk of sarcopenia with baseline cognitive status Baseline characteristics of participants across different patterns of long-term cognitive function Sensitivity analyses of the association between alternative lifestyle definitions and incident sarcopenia A directed acyclic graph depicting the causative relationships among baseline cognitive impairment, lifestyle variables, and the occurrence of sarcopenia. MCI, mild cognitive impairment.